TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26394259
Drug: +IN-βG yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: +IN-βG yogurt (1.9 g of inulin and 0.5 g of β-glucan)
Study: 26394259
Drug: Fibre-enriched formulations
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre-enriched formulations (2.4 g of inulin and 0.5 g of β-glucan)
Study: 26394259
Drug: Yogurt with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt with 0.5 g of β-glucan
Study: 21241922
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg, 3 times daily for 7 days (2 days before and 4 days after surgery)
Study: 21241922
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 times daily for 7 days (2 days before and 4 days after surgery)
Study: 19225118
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fat infusion)
Study: 10857213
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 2 mg daily in combination with ethinylestradiol (EE2) 35 mg or 50 mg
Study: 10857213
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA) 2 mg daily
Study: 9088884
Drug: Oral SRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SRI drugs (standardized treatment for 10 weeks)
Study: 8256902
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (2.5 mg)
Study: 8256902
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (7.5 mg cumulative dose)
Study: 8256902
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (15.0 mg cumulative dose)
Study: 8256902
Drug: MDI albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI albuterol (100 puffs, 9 mg)
Study: 3236320
Drug: Indapamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5 mg/day)
Study: 22544004
Drug: Open-label olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label olanzapine treatment (2.5 or 5 mg/d, increased up to 20 mg/d in study 1 or 15 mg/d in study 2)
Study: 22544004
Drug: Open-label olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label olanzapine treatment after placebo during the acute phase
Study: 22544004
Drug: Open-label olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label olanzapine treatment after olanzapine during the acute phase
Study: 18922335
Drug: Pillar palate
Normalized name: palmate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pillar palate implants
Study: 12458116
Drug: Combined antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiemetic strategy including nursing intervention program (increased access to support and increased information) and antiemetics based on high‐dose metoclopramide and dexamethasone
Study: 12458116
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic treatment during the 1980s
Study: 8081005
Drug: CY-TBI (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY-TBI (60 mg/kg cyclophosphamide on each of 2 successive days followed by 6 fractions of total body irradiation each of 2.0 Gy)
Study: 8081005
Drug: BU-CY (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: BU-CY (16 mg/kg busulfan over 4 days followed by 60 mg/kg cyclophosphamide on each of 2 successive days)
Study: 2526824
Drug: Acitretin 10
Normalized name: acitretin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 10 mg/day
Study: 2526824
Drug: Acitretin 75
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin 75 mg/day
Study: 2127045
Drug: Xylitol infusion
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol infusion
Study: 12139223
Drug: Halofantrine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (500 mg)
Study: 12139223
Drug: Co-artemether (80/480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-artemether (80/480 mg)
Study: 8588061
Drug: 75-100 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-100 mg/day amitriptyline (n=16)
Study: 8588061
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day amineptine (n=10)
Study: 8588061
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with classic tricyclic antidepressants
Study: 8588061
Drug: Dopaminergic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic drugs
Study: 6817270
Drug: 1% glycopyrrolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% glycopyrrolate roll-on lotion and cream
Study: 6817270
Drug: Topical scopolamine
Normalized name: scopolamine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical scopolamine (solution and cream)
Study: 6817270
Drug: Glycopyrrolate (roll-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (roll-on lotion, solution, and cream)
Study: 31468214
Drug: Fluid-restrictive vasopressor-dominated
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid-restrictive vasopressor-dominated hemodynamic support (FRV) with norepinephrine concentration of 0.065±0.020 μg/kg/min
Study: 31468214
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid administration (LFA) with fluid administration of 5.1±2.2 ml/kg/h
Study: 31617141
Drug: Stiripentol as
Normalized name: stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stiripentol as adjunctive therapy
Study: 16313817
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel plus carboplatin
Study: 7775623
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (Estraderm‐TTS 100)
Study: 7775623
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (Premarin, 1.25 mg)
Study: 2310655
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g day-1 acetylsalicylic acid
Study: 2310655
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g day-1 paracetamol
Study: 2310655
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g day-1 acetylsalicylic acid and 1.5 g day-1 paracetamol (combination)
Study: 2310655
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g day-1 acetylsalicylic acid (separated by washout phases)
Study: 2310655
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four drug schedules
Study: 6184562
Drug: VER (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: VER (80 mg t.i.d.)
Study: 6184562
Drug: NIF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIF (10 mg t.i.d.)
Study: 6184562
Drug: VER (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: VER (160 mg t.i.d.)
Study: 6184562
Drug: VER (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: VER (80 mg t.i.d.) and NIF (10 mg t.i.d.)
Study: 30849076
Drug: Open-loop insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-loop insulin delivery
Study: 25901546
Drug: Aerosolized albuterol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized albuterol
Study: 9110517
Drug: Integrated mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated mental health and substance abuse treatment program
Study: 9110517
Drug: Standard psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychiatric hospital treatment
Study: 30430201
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment other than the prescribed medication (Control)
Study: 28399981
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors plus insulin
Study: 26370528
Drug: Protective group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective group (Group P) - tidal volume of 6 mL/kg, FiO2 of 80%, PEEP of 5 cm H2O
Study: 26370528
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (Group C) - tidal volume of 8 mL/kg, FiO2 of 100%
Study: 20824894
Drug: Saffron 60
Normalized name: SAFFRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron 60 mg/day for 26 weeks
Study: 15624283
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) 1.2 g/d
Study: 11577791
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inhaled corticosteroids
Study: 9267685
Drug: Sertindole administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole administered as tablets after fasting
Study: 9267685
Drug: Sertindole administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole administered as tablets with food
Study: 9267685
Drug: Sertindole administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole administered as tablets with Maalox (antacid)
Study: 9267685
Drug: Sertindole administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole administered as solution
Study: 9267685
Drug: Sertindole administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole administered as tablets under fasting conditions
Study: 1980611
Drug: Anticholinergic medication
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic medication
Study: 7905226
Drug: No antiparkinsonian
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiparkinsonian drug
Study: 28627275
Drug: 4-week mixed-modality
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week mixed-modality supervised exercise program (4 times a week, twice a day)
Study: 15142103
Drug: Mandibular implant‐retained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant‐retained overdentures
Study: 24417762
Drug: Implant‐supported fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant‐supported fixed partial dentures (FPDs)
Study: 12807998
Drug: Ibuprofen (Cmax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (Cmax >50 microg/ml)
Study: 12807998
Drug: Ibuprofen (Cmax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (Cmax <50 microg/ml)
Study: 11212064
Drug: Atenolol and
Normalized name: atenolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol and hydralazine (as secondary and tertiary drugs)
Study: 8857564
Drug: Tacrolimus high
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus high zone (0.6-1.2 ng/ml) in Primary Biliary Cirrhosis study group
Study: 8857564
Drug: Tacrolimus low
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus low zone (0.1-0.6 ng/ml) in Primary Biliary Cirrhosis study group
Study: 8857564
Drug: Tacrolimus concentration
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus concentration range (0.3-0.7 ng/ml) in Multiple Sclerosis study group
Study: 1642347
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (0.027 mg) with 6 ml sodium chloride 0.9% intravenously
Study: 1642347
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (0.027 mg) with six sprays of sodium chloride 0.9% intranasally
Study: 6424496
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition via central veins (Control)
Study: 17652730
Drug: Other antiepileptic
Normalized name: Other antiepileptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiepileptic drugs
Study: 27177240
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low HDL-C (<30 mg/dL)
Study: 27177240
Drug: Higher HDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher HDL-C (≥30 mg/dL)
Study: 24479409
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of rAd-p53 plus chemotherapy (group I, n = 35)
Study: 24479409
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of rAd-p53 plus placebo chemotherapy (group II, n = 33)
Study: 24479409
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of placebo rAd-p53 plus chemotherapy (group III, n = 31)
Study: 24479409
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of rAd-p53 plus chemotherapy (group I)
Study: 21208247
Drug: Oxycodone/paracetamol (5/325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/paracetamol (5/325 mg), four times daily for 3 days
Study: 21208247
Drug: Oxycodone/paracetamol (5/325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/paracetamol (5/325 mg)
Study: 20646695
Drug: 12 oz
Normalized name: Oval Amber 12 oz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 oz oral sulfate solution (OSS) given in equally divided doses the evening before and the morning of colonoscopy
Study: 20646695
Drug: 12 oz
Normalized name: Oval Amber 12 oz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 oz oral sulfate solution (OSS)
Study: 20646695
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L sulfate-free electrolyte lavage solution (SF-ELS)
Study: 16036344
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin C 100 mg, vitamin E 100 mg, β-carotene 6 mg, selenium 50 µg) for 12 weeks
Study: 9541437
Drug: Alpha-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (50 mg per day)
Study: 9541437
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg per day)
Study: 7897161
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydroxyzine
Study: 4823547
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg hydroxyzine
Study: 4823547
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hydroxyzine
Study: 4823547
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg pentobarbital
Study: 4823547
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg pentobarbital
Study: 26553084
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) guided antibiotic treatment
Study: 26553084
Drug: Empiric antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotic therapy (Control)
Study: 22117987
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg/kg loading dose followed by infusion of 30 μg/kg per min)
Study: 19857748
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of CD133+ stem cells
Study: 16835340
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg p.o. bid)
Study: 16835340
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg p.o. bid)
Study: 8858786
Drug: Statistical models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statistical models for treatment comparison
Study: 8858786
Drug: Maximum likelihood
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum likelihood (ML) and restricted maximum likelihood (REML) approaches
Study: 3433091
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetylsalicylic acid (ASA) and dihydroergotamine (DHE)
Study: 18326594
Drug: Dietary betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary betaine (approximately 517 mg)
Study: 18326594
Drug: Supplementary betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplementary betaine (approximately 500 mg)
Study: 18326594
Drug: High-betain meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-betain meal (approximately 517 mg)
Study: 18326594
Drug: High-betain and
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-betain and high-choline meal (approximately 517 mg betaine, approximately 622 mg choline)
Study: 18326594
Drug: Choline supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplement (500 mg)
Study: 10979637
Drug: Sulpirid monotherapy
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpirid monotherapy (200-450 mg/day)
Study: 10979637
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (combined treatment with spasmolytic, bacterial and cholagogic drugs)
Study: 8629624
Drug: Very low-protein
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low-protein diet (0.28 g/kg/d) supplemented with keto acids-amino acids (0.28 g/kg/d)
Study: 17162142
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.58 g/kg/d)
Study: 1465791
Drug: Fish-oil administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil administration in cyclosporine-treated patients
Study: 23920031
Drug: Aggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive hydration with lactated Ringer's solution (3 mL/kg/h during the procedure, a 20-mL/kg bolus after the procedure, and 3 mL/kg/h for 8 hours after the procedure)
Study: 23920031
Drug: Standard hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydration with lactated Ringer's solution (1.5 mL/kg/h during and for 8 hours after procedure)
Study: 23920031
Drug: Aggressive hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive hydration with lactated Ringer's solution
Study: 23920031
Drug: Standard hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydration with lactated Ringer's solution
Study: 20223555
Drug: Azithromycin 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1.5% eye drops, twice daily for 3 days
Study: 20223555
Drug: Tobramycin 0.3%,
Normalized name: Tobramycin 0.3%, Dexamethasone 0.1% Ophthalmic drops, suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3%, 1 drop every 2 hours for 2 days, then four times daily for 5 days
Study: 18715414
Drug: Dinoprostone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (3 mg initially, followed by 3 mg after 6 hours)
Study: 15983179
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (400-800 IU daily)
Study: 12072669
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) with 400 mg of norfloxacin once daily preoperatively and postoperative treatment with 2 mg of colistin, 1.8 mg of tobramycin, and 10 mg of amphotericin B, four times daily, until postoperative day 30.
Study: 12072669
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with similar regimen of placebo drugs.
Study: 9797418
Drug: 5-day cefixime
Normalized name: (-)-cefixim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day cefixime 400 mg
Study: 9797418
Drug: 10-day cefixime
Normalized name: (-)-cefixim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day cefixime 400 mg
Study: 101296
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of 6-mercaptopurine and methotrexate
Study: 101296
Drug: Further 3
Normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further 3 month-doses of intrathecal methotrexate and dexamethasone
Study: 101296
Drug: Intensification, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification, daily maintenance, and further intrathecal therapy
Study: 27072971
Drug: Plasma‐Lyte A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma‐Lyte A 100 mL (P100 group)
Study: 27072971
Drug: Plasma‐Lyte A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma‐Lyte A 250 mL (P250 group)
Study: 27072971
Drug: Plasma‐Lyte A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma‐Lyte A 500 mL (P500 group)
Study: 27072971
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline 500 mL (N500 group)
Study: 27072971
Drug: Gelofusine 500
Normalized name: Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofusine 500 mL (G500 group)
Study: 20637149
Drug: Midazolam (0.1‐0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1‐0.3 mg/kg)
Study: 20637149
Drug: Diazepam (0.3‐0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.3‐0.5 mg/kg)
Study: 20637149
Drug: Midazolam (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (maintenance dose 1‐8 mg/kg per hour)